Dibenzo-alpha pyrones

Other Names

6H-benzo[c]chromen-6-ones6H-dibenzo[b,d]pyran-6-onesDBPsDCPsdibenzo-alpha-pyranonesdibenzo-alpha-pyrone chromoproteinsdibenzo-α-pyranonesdibenzo-α-pyronesheptaketide coumarinshydroxylated dibenzo-α-pyronesoxygenated dibenzo-alpha-pyrones

Synopsis

Dibenzo-Alpha-Pyrones (DBPs): A Comprehensive Reference

1. Identity: Chemical and Botanical Classification

Dibenzo-alpha-pyrones (abbreviated DBPs; also written as dibenzo-α-pyrones or DAPs) are a class of naturally occurring organic compounds built around a core bicyclic scaffold in which two benzene rings are connected via a pyranone (lactone) ring. Urolithin A, one of the most studied members of the class, belongs to the dibenzo[b,d]pyran-6-one family of compounds, characterized by a core structure in which two benzene rings are connected via a pyranone ring; chemically, these molecules are also described as benzocoumarins or dibenzopyrones.

The dibenzo-α-pyrone scaffold is the basic structural unit of a group of naturally occurring chemicals mainly formed by microbial species, such as bacteria or filamentous fungi. When substituted with multiple hydroxy groups, those metabolites belong to the chemical class of polyphenols, from which many representatives are regarded as beneficial for human health, mostly due to anti-oxidative and chemopreventive effects.

Natural dibenzo-α-pyrones are an important group of metabolites derived from fungi, mycobionts, plants, and animal feces. They exhibit a variety of biological activities such as toxicity on humans and animals, phytotoxicity, as well as cytotoxic, antioxidant, antiallergic, antimicrobial, antinematodal, and acetylcholinesterase inhibitory properties. Dibenzo-α-pyrones are biosynthesized via the polyketide pathway in microorganisms or metabolized from plant-derived ellagitannins and ellagic acid by intestinal bacteria. At least 53 dibenzo-α-pyrones have been reported in the past few decades.

1.1 Principal Natural Sources

DBPs in the context of dietary supplementation are most closely associated with shilajit (also spelled shilajeet, salajeet, or mumie/mumijo in Central Asian traditions). Shilajit is a widely used natural herbo-mineral in Ayurveda, the traditional Indian system of medicine. It is a sticky brown to blackish physiologically active organic matter exuded from steep rocks in many mountain ranges of the world, especially the Himalayas of the Indian subcontinent.

Shilajit is composed of rock humus, rock minerals, and organic substances that have been compressed by layers of rock mixed with marine organisms and microbial metabolites. It oozes out of the rocks in the Himalayas at higher altitudes ranging from 1,000–5,000 meters as a black mass and is regarded as a maharasa (super-vitalizer) in Ayurveda, the traditional Indian system of medicine, dating back to 3,500 B.C.

Shilajit is also found in the high-altitude regions of the Altai, Caucasus, and other mountain ranges. It is a complex phytomineral substance formed over centuries through the gradual decomposition of plant and microbial matter, enriched with a diverse range of organic and inorganic constituents.

A second major natural source of DBPs arises through gut microbial biotransformation. Urolithins (dibenzo-pyran-[b,d]-6-one derivatives) are human gut microbiota metabolites produced from the natural food antioxidant ellagic acid. Urolithins are better absorbed than ellagic acid and demonstrate biological activities that suggest they are responsible for the health effects observed after consuming ellagitannin- and ellagic acid-containing foods.

A third source—of concern rather than benefit—consists of food-contaminating molds. DBPs biosynthesized by food-contaminating molds, such as mycotoxin alternariol (AOH), are regarded as potential carcinogens due to their ability to damage DNA and to potentially induce endocrine-disruptive effects.

1.2 Key Individual Compounds in the DBP Class

Fulvic acid complex, derived from shilajit, is an assembly of naturally occurring low- and medium-molecular-weight compounds comprising oxygenated dibenzo-alpha-pyrones (DBPs), both in reduced and oxidized form, as the core nucleus, and acylated DBPs and lipids as partial structural units, along with fulvic acids.

The primary bioactive DBPs identified in shilajit are:

3-Hydroxydibenzo-α-pyrone (3-OH-DBP) — also referred to as Urolithin B in urolithin nomenclature
3,8-Dihydroxydibenzo-α-pyrone [3,8-(OH)₂-DBP] — also known as Urolithin A

The mitochondrial deficiency associated with aging has a link with systemic deficiencies of coenzyme Q10 (CoQ10) and of two of its endogenous functional associates, namely 3-hydroxydibenzo-α-pyrone (3-OH-DBP) and 3,8-dihydroxydibenzo-α-pyrone [3,8-(OH)₂-DBP]. Mitochondrial targeting of the two DBPs, isolated from shilajit, and of CoQ10 could be formidable strategies to augment antioxidant defense and energy generating elements for restoring normal mitochondrial functions. DBPs, as also their fatty-acyl and amino-acyl conjugates, occur in animal mitochondria and in blood where they act in tandem with CoQ10 in the electron transport chain.

In addition to free DBP monomers, shilajit contains DBPs in complexed forms: active constituents of shilajit include dibenzo-alpha-pyrones, dibenzo-alpha-pyrone-chromoproteins (DCPs), and fulvic acids. Fulvic acid complex material derived from alluvial sources lacks DBPs; instead, the core nucleus of alluvial fulvic acid is comprised of benzoic acid. This distinction is important for quality assessment of shilajit preparations.

For the Alternaria mold subgroup, the primary DBP members are alternariol (AOH) and alternariol monomethyl ether (AME). Alternariol (AOH) and alternariol monomethyl ether (AME) represent the most studied Alternaria metabolites. Together with other compounds including altenuene (ALT), iso-altenuene (iso-ALT), or altenuisol (ATL), they form the dibenzo-α-pyrone group of Alternaria toxins.

1.3 Common Preparations and Forms

In the supplement trade, DBPs are delivered primarily through shilajit products, which are standardized to defined minimum DBP content. Shilajit used in clinical research has been standardized to contain not less than 60% w/w of total bioactives, which include not less than 50% w/w of fulvic acids, not less than 0.3% w/w of dibenzo-α-pyrones, and not less than 10% w/w of dibenzo-α-pyrone chromoproteins, as quantified by HPLC using external standards.

Commercial preparations appear in multiple physical forms including: raw resin exudate, purified resin, powder extracts, capsules, and tablets. The bioactive composition of shilajit includes fulvic acid (15–20%), humic acid, dibenzo-alpha-pyrones (DBPs), and over 80 minerals in their ionic form.

DBPs also arise endogenously in humans as urolithins, following consumption of foods rich in ellagitannins (e.g., pomegranates, walnuts, strawberries, raspberries). Urolithin A (UA), a metabolite formed by ellagitannin-degrading gut bacteria, is extensively researched and marketed as a health-promoting agent in the scope of functional foods, or even as a therapeutic agent to improve muscle health.

2. Traditional and Historical Use

Shilajit (also known as salajit or mumie) is a blackish-brown exudate traditionally derived from rocks in the Himalayan mountain ranges, formed over centuries through the decomposition of plant matter and microbial metabolites. This substance has been used for millennia in Ayurvedic and traditional medicine systems as a rasayana (rejuvenator) to enhance physical performance, improve vitality, and promote longevity.

Shilajit (mumie), a natural multi-component herbo-mineral ethnomedicinal food, is used as a traditional medicine for enhancing the quality of life and for management of health ailments in many countries of the world. Use of shilajit as an adaptogen, aphrodisiac, rejuvenator, and anti-aging substance is mentioned in many ancient texts.

Shilajit is an important, known component of Ayurvedic medicine given its characteristics as a rasayana. Health benefits such as an increase in longevity, rejuvenating, and arresting aging roles have been attributed to it.

Shilajit is used as a traditional medicine for enhancing the quality of life and for management of health ailments in many countries of the world. Use of shilajit as an adaptogen, aphrodisiac, rejuvenator, and anti-aging substance is mentioned in many ancient texts.

The substance is also documented in Central Asian and Middle Eastern traditions under the name mumie or mumijo, used similarly as a generalized tonic and wound healer. Shilajit is a mineral-rich resin that has a long history of use as a rejuvenator (rasayana) in Ayurvedic medicine to treat various ailments such as arthritis, infertility, and cognitive decline.

Traditional Ayurvedic preparation involved purification steps. Traditional methods employed in Ayurveda involve several steps to ensure the removal of impurities. These methods include extraction (collecting shilajit in its raw form), filtration (removing insoluble impurities such as dirt and plant matter), purification (utilizing heat and herbal mixtures to detoxify the substance), and dehydration (removing moisture to create a concentrated form suitable for consumption).

3. Botanical and Biological Origin: Biosynthesis and Formation

Several plant organisms may generate the plant precursors of shilajit, including molds such as Barbula, Fissidens, Minium, and Thuidium, and other species like Asterella, Dumortiera, Marchantia, Pellia, Plagiochasma, and Stephenrencella-Anthoceros.

Two distinct biosynthetic routes produce natural DBPs:

3.1 Polyketide Pathway (Microbial Biosynthesis)

In microorganisms, dibenzo-α-pyrones are biosynthesized via the polyketide pathway. Polyketide synthase (PKS) is one of the postulated core enzymes in the biosynthesis of 6H-dibenzo[b,d]pyran-6-ones (i.e., alternariol, AME) in Alternaria alternata. In a draft genome sequence of A. alternata, 10 putative PKS-encoding genes were identified.

The biosynthesis pathway is described mainly for filamentous fungi, particularly the genus Alternaria. A polyketide synthase encoded by the pksJ gene was found to be critical for the production of the two most prevalent DAPs, AOH and alternariol 9-methyl ether (AME) by Alternaria alternata. Furthermore, the production of these and similar DAPs was also reported in other Alternaria, Acremonium, Cephalosporum, and Hyalodendriella spp.

3.2 Ellagitannin/Gut Microbial Pathway (Urolithin Formation)

Urolithins are produced in different animals after the intake of ellagitannins and ellagic acid. Ellagitannins are hydrolyzed to ellagic acid in the acidic environment of the stomach by the action of the intestinal bacteria. The majority of ellagic acid reaches the colon, where it is metabolized by the gut microbiota into hydroxylated 6H-dibenzo[b,d]pyran-6-one derivatives known as urolithins.

While studies have shown that Gordonibacter urolithinfaciens and Gordonibacter pamelaeae play a role in the conversion of ellagic acids and ellagitannins into urolithin A, the microorganisms responsible for the complete transformation into the final urolithins are still unknown. The efficiency of the conversion of ellagitannins into urolithin A significantly varies in humans, and some individuals do not show any conversion.

Urolithin A production varies across individuals because microbial conversion requires specific bacterial taxa (for example, Bifidobacterium) in the colon.

There are isolated reports of DAP derivatives being formed by plants, but the two main ways that they are produced in or from food commodities are (a) the complete biosynthesis as secondary metabolites of molds, or (b) the biodegradation of ellagitannins by intestinal bacteria.

4. Key Constituents and Active Compounds

The active constituents of shilajit contain dibenzo-alpha-pyrones and related metabolites, small peptides (constituting non-protein amino acids), some lipids, and carrier molecules (fulvic acids).

Shilajit is endowed with anti-stress, memory and energy-enhancing, antioxidant, anti-inflammatory, antidiabetic, spermatogenic, neuroprotective, antiulcer, and wound-healing activities. These pharmacological effects are mainly attributed to the presence of humic acid, fulvic acid, dibenzo-α-pyrones, dibenzo-α-pyrone chromoproteins, and trace elements.

Hydroxylated dibenzo-α-pyrones (DBPs) and their acyl and aminoacyl derivatives are the key bioactive components of shilajit.

In the wider natural DBP family, structural substitution patterns critically determine bioactivity. The hydroxy group at C1 is a common feature of most natural DAPs. Methylation of C5, as well as hydroxylation of C11, are common in biosynthesized DAPs but are not featured in ellagitannin biodegradation products.

5. Mechanisms of Action

5.1 Mitochondrial Electron Transport and ATP Synthesis

The most extensively proposed mechanism for shilajit DBPs is their action within the mitochondrial electron transport chain (ETC). Administration of CoQ10 alone, in mitochondrial deficiency states, could not restore normal mitochondrial functions. The concomitant targeting of DBPs and CoQ10 to mitochondria would augment energy (ATP) synthesis and protect redox states of CoQ10 from oxidative degradation.

The concomitant targeting of DBPs and CoQ10 to mitochondria would augment energy (ATP) synthesis and protect redox states of CoQ10 from oxidative degradation. The findings adduce evidence of augmentation of the concentrations of DBPs and CoQ10 in mitochondria when administered from exogenous sources through intra-peritoneal/oral routes.

The mechanisms delineated in studies of oxido-reductase reactions, operating in the electron transport chain of animal mitochondria to generate ATP, point to a persuasive role of concurrent application of oxygenated dibenzo-α-pyrones (DBPs) — specifically 3,8-(OH)₂-DBP (and equivalents) — and coenzyme Q10 (CoQ10) in animals and humans. Furthermore, to restore the age-related depreciation in the systemic concentration of DBPs in humans, it would be logical to administer DBPs from exogenous sources (such as obtained from shilajit or ammonites) along with CoQ10.

5.2 Antioxidant Activity

Dibenzo-α-pyrones demonstrate their anti-oxidant effects through mechanisms involving their phenolic structures, which allow them to donate hydrogen atoms and neutralize free radicals. They exhibit significant antioxidant activity, predominantly via the hydrogen atom transfer (HAT) mechanism.

Shilajit has been extensively investigated for its pharmacological effects, with studies suggesting its role as an adaptogen, cognitive enhancer, and immunomodulator. The presence of fulvic acid and dibenzo-α-pyrones is associated with its potent antioxidant activity, which mitigates oxidative stress.

5.3 Mitophagy and Autophagy Induction

Literature on genotoxic, estrogenic, and endocrine-disruptive effects, as well as on the induction of the cellular anti-oxidative defense system, anti-inflammatory properties, the inhibition of kinases, the activation of mitophagy, and the induction of autophagy, has been gathered and critically reviewed across the broader natural DAP class. For the beneficial urolithin subgroup, induction of mitophagy (selective autophagy of mitochondria) is considered a primary mechanism underlying muscle health benefits.

5.4 Cholinergic and Neurological Mechanisms

Shilajit exhibits antioxidant, immunomodulatory, anti-inflammatory, adaptogenic, and antidyslipidemic activities. It has cholinergic and parasympathomimetic effects.

5.5 Effects on Testosterone Biosynthesis

Animal-model research has examined androgenic mechanisms. Shilajit enhances testosterone biosynthesis by activating enzymes like 3β-HSD and 17β-HSD. Shilajit also reduces testicular oxidative stress by increasing antioxidant enzyme activity (SOD) and decreasing lipid peroxidation (LPO).

6. Scientific Evidence by Area of Use

6.1 Energy Metabolism and Physical Performance

Preclinical evidence (animal): Of the two oxygenated dibenzo-α-pyrones present in purified shilajit preparations, 3-OH-DBP was found to work better in protecting animal organisms from different forms of oxidative stress. 3-OH-DBP significantly improved content of ATP, AEC values, and ATP/ADP ratio in blood in albino mice engaged in forced swimming.

Significant improvement was also observed in the ATP/ADP ratio in blood of DBP-treated animals in the restraint stress model, with indications of improvement also in the other parameters.

Human clinical evidence: A randomized, placebo-controlled study examined shilajit's effects on muscle strength and endurance. The purpose of this study was to examine the effects of 8 weeks of shilajit supplementation at 250 mg·d⁻¹ (low dose) and 500 mg·d⁻¹ (high dose) versus placebo on maximal voluntary isometric contraction (MVIC) strength, concentric peak torque, fatigue-induced percent decline in strength, and serum hydroxyproline (HYP). The subjects were randomly assigned to the high dose, low dose, or placebo group (each group: n = 21).

A more recent open-label pilot study assessed physical outcomes using shilajit resin. This was an open-label, single-arm pilot clinical study conducted over 28 days in 25 healthy male participants aged 21–55 years. Participants received 500 mg/day of shilajit resin (250 mg twice daily). Primary outcomes included changes in muscle strength (one-repetition maximum leg press), muscle endurance, grip strength, fatigue severity, and rating of perceived exertion. Secondary outcomes included aerobic capacity (VO₂ max), body composition parameters, inflammatory markers like CRP levels, muscle damage markers such as creatine kinase (CK) and lactate dehydrogenase (LDH), and hormonal markers (total testosterone).

Evidence strength: Studies conducted in animal models tend to support its use as a "revitalizer," enhancing physical performance and relief from fatigue with enhanced ATP production. Human clinical evidence remains limited in sample size and study duration.

6.2 Testosterone and Male Reproductive Health

Clinical evidence: A randomized, double-blind, placebo-controlled clinical trial examined testosterone effects. Purified shilajit, an Ayurvedic rasayana, was evaluated in healthy volunteers aged between 45 and 55 years for its effect on the male androgenic hormone testosterone in a randomised, double-blind, placebo-controlled clinical study at a dose of 250 mg twice a day. Treatment with shilajit for consecutive 90 days revealed that it has significantly (P < 0.05) increased total testosterone, free testosterone, and dehydroepiandrosterone (DHEAS) compared with placebo. Gonadotropic hormones (LH and FSH) levels were well maintained.

A separate clinical study focused on spermatogenic activity. Published in Andrologia, this clinical study evaluated the spermatogenic activity of processed shilajit (100 mg twice daily for 90 days) in 28 oligospermic men, reporting a 23.5% increase in serum testosterone, 61.4% increase in total sperm count, and significant improvements in sperm motility and morphology.

Evidence strength: These findings come from small to moderate-sized clinical trials. While the randomized, double-blind design of the testosterone study is notable, replication in independent, larger trials with different populations is needed before broad conclusions can be drawn.

6.3 Cognitive Function and Neuroprotection

Dibenzo-α-pyrone (DBαP) is a vital constituent of shilajit, an herbal drug that has shown reported results as a nutritive tonic, analgesic, and immunomodulator with anti-aging, anti-oxidant, anti-Alzheimer, adaptogenic, and anti-ulcerogenic activity.

A review published in the International Journal of Alzheimer's Disease found that shilajit exhibits neuroprotective properties due to its fulvic acid and antioxidant content. It may help maintain brain function, support memory, and reduce inflammation associated with aging.

Neuroprotective effects of DBP derivatives were examined in an animal model. One study group evaluated the neuroprotective effect of butylamine derivatives of dibenzo-α-pyrones in a Wistar rat model of neuronal ischemia by sciatic nerve ligation. Neuronal ischemia was induced in the rats; DBαP treatment commenced on the 1st day of the study and lasted for 14 days. Cold and warm allodynia were checked. Biochemical estimation regarding protein level, MDA, GSH, catalase, SOD, nitrite, cytokine estimation by ELISA assay, and western blotting were performed.

Evidence strength: Neuroprotective evidence for DBPs specifically is currently predominantly preclinical (animal and in vitro). More investigations at the basic biological level as well as clinical trials are necessary to understand how organic molecules of shilajit and particularly fulvic acid and dibenzo-α-pyrones function.

6.4 Anti-Inflammatory Activity

Urolithins are dibenzopyranone metabolites that exert anti-inflammatory activity in vivo and are produced by the gut microbiota from the dietary polyphenols ellagic acid and ellagitannins.

Shilajit is composed of humus and organic plant material, and its active constituents include dibenzo-alpha-pyrones, dibenzo-alpha-pyrone-chromoproteins, and fulvic acids. It exhibits antioxidant, immunomodulatory, anti-inflammatory, adaptogenic, and antidyslipidemic activities.

Evidence strength: Anti-inflammatory bioactivity has been documented for urolithins in cell-based studies and animal models. Robust human clinical trials demonstrating significant reductions in validated inflammatory biomarkers attributable specifically to the DBP fraction remain limited.

6.5 Mitophagy and Muscle Health (Urolithin A)

Urolithin A (UA), a metabolite formed by ellagitannin-degrading gut bacteria, is extensively researched and marketed as a health-promoting agent in the scope of functional foods, or even as a therapeutic agent to improve muscle health.

Urolithin A (UA), a metabolite of dietary ellagitannins produced by the gut microbiome, is a potential dual-purpose bioactive compound that may interfere with the shared pathogenic pathways linking colorectal cancer (CRC) and type 2 diabetes mellitus (T2DM). A recent review summarizes preclinical and clinical data on UA's mechanisms and therapeutic potential. In CRC models, UA promotes G2/M cell cycle arrest, triggers both intrinsic and extrinsic caspase-mediated apoptosis, enhances CD8+ T-cell mitophagy and memory functions, and suppresses Wnt/β-catenin signaling.

Evidence strength: Urolithin A muscle health research includes some human clinical trials, which represent the strongest level of human evidence within the natural DBP category; however, many mechanistic data points remain from preclinical or in vitro work.

6.6 Metabolic Health and Body Weight

A method of using dibenzo-alpha-pyrones (DBPs) has been proposed wherein a subject is administered one or more DBPs resulting in decreased body weight gain. In one embodiment, a 3-OH-DBP, 3,8-(OH)₂-DBP, or a combination thereof is administered to an individual to control body weight gain.

Research has comprehensively examined the role and mechanisms of Urolithin A in ameliorating obesity and related metabolic disorders. The in vivo production of UroA is strictly dependent on specific gut microbiota, and the substantial inter-individual variation in this metabolic capacity directly influences population responsiveness to ellagitannin-rich dietary interventions.

Evidence strength: Weight/metabolic evidence is primarily from preclinical models and mechanistic patent filings. Clinical trial data specifically demonstrating DBP-mediated weight changes in humans are not yet established.

6.7 Overall Evidence Assessment

A 2024 systematic review assessed clinical efficacy and safety of shilajit across multiple human studies. It concludes that while the results are promising, more large and rigorous trials are needed. Despite numerous health claims, there are still major gaps in our understanding of shilajit's mechanism of action, variability in efficacy, and toxicity profile.

7. Body Systems and Health Areas Associated with DBPs

Mitochondria and cellular energy: ATP generation via the electron transport chain; CoQ10 stabilization
Musculoskeletal system: Fatigue resistance, muscle strength maintenance, connective tissue (via serum hydroxyproline)
Endocrine/reproductive system: Testosterone and DHEAS regulation; spermatogenesis support
Central nervous system: Neuroprotection, acetylcholinesterase inhibition, potential anti-Alzheimer activity
Immune system: Immunomodulation, adaptogenic activity
Gastrointestinal system: Urolithin production from ellagitannin metabolism; anti-ulcer properties
Cardiovascular/metabolic system: Antidyslipidemic, antioxidant protection

Shilajit's active constituents include dibenzo-alpha-pyrones, dibenzo-alpha-pyrone-chromoproteins, and fulvic acids. It exhibits antioxidant, immunomodulatory, anti-inflammatory, adaptogenic, and antidyslipidemic activities. It also has cholinergic and parasympathomimetic effects.

8. Dosage Forms and Dosages Reported in Studies

Clinical studies have used the following dosage regimens for shilajit preparations standardized to contain DBPs:

250 mg twice daily (500 mg/day) for 90 consecutive days — used in a randomized, double-blind, placebo-controlled trial evaluating testosterone levels in healthy male volunteers aged 45–55.
250 mg/day (low dose) and 500 mg/day (high dose) — used in an 8-week trial examining effects on isometric contraction strength, concentric peak torque, fatigue-induced percent decline in strength, and serum hydroxyproline.
500 mg/day (250 mg twice daily) — used in a 28-day open-label pilot study in 25 healthy male participants aged 21–55 years.
100 mg twice daily (200 mg/day) for 90 days — used in a clinical study evaluating spermatogenic activity in 28 oligospermic men.

With respect to DBP content specification in standardized products: preparations used in clinical research have been standardized to contain not less than 0.3% w/w of dibenzo-α-pyrones, as quantified by HPLC.

It should be noted that DBPs themselves have not yet been isolated and dosed as standalone pharmaceutical-grade ingredients in published large-scale human clinical trials. The doses above represent shilajit complex preparations in which DBPs are a defined fraction.

9. Safety Considerations and Interactions

9.1 Heavy Metal Contamination

Shilajit resin continues to raise safety concerns due to persistent heavy metal contamination. Despite purification claims, peer-reviewed studies and regulatory alerts indicate unsafe levels of lead (Pb), arsenic (As), mercury (Hg), and other toxic metals in several resin samples.

Because shilajit forms from the natural decomposition of organic matter and concentrates minerals from its geological surroundings over thousands of years, it can also accumulate heavy metals present in the rocks and soil. The mountain environment where shilajit originates determines not only its beneficial mineral content but also its potential contaminants.

A specific heavy metal of concern identified in recent analytical research is thallium. Thallium contents were detected up to 0.226 µg/g in natural shilajit, and up to 0.5 µg/g in supplements studied. Consumption of one pill of supplement introduces up to 0.095 µg of thallium to the body. Thallium is highly toxic to humans, animals, plants, and microorganisms, presenting a significant health hazard. It can be absorbed through the skin and mucous membranes, quickly spreading throughout the body.

9.2 The Dual Nature of the DBP Class: Beneficial vs. Hazardous Subgroups

Natural dibenzo-α-pyrones (DAPs) can be viewed from two opposite angles. From one angle, the gastrointestinal metabolites urolithins are regarded as beneficial, while from the other, the emerging mycotoxin alternariol and related fungal metabolites are evaluated critically with regards to potential hazardous effects.

Among the best studied Alternaria mycotoxins, the dibenzo-α-pyrone alternariol (AOH) has been reported to induce DNA strand breaks and to poison topoisomerases, exerting genotoxic effects.

The dibenzo-α-pyrones alternariol (AOH) and its monomethyl ether (AME) have been reported to induce DNA strand breaks by poisoning human topoisomerases I and II and inducing oxidative stress.

Alternariol (AOH), an emerging mycotoxin, contaminates various food products. AOH is reported to be genotoxic and to induce oxidative stress. Previous results showed that AOH is also estrogenic and acts as an androgen receptor (AR) agonist, suggesting that it might act as an endocrine-disrupting chemical.

Despite the fact that AOH is an emerging mycotoxin that raises increasing concerns regarding its health effects, no regulatory limits have been established on its maximal threshold concentrations in food, animal feed, and beverages.

9.3 Distinguishing Beneficial from Hazardous DAPs

Comparing published data suggests similar bioactivity profiles of alternariol and urolithin A. Thus, the current stratification into hazardous Alternaria toxins and healthy urolithins seems debatable. An extrapolation of bioactivities to the other DAP sub-class could serve as a promising base for further research. Conclusively, urolithins should be further evaluated toward high-dose toxicity, while alternariol derivatives could be promising chemicals for the development of therapeutics.

9.4 General Safety Profile of Shilajit-Derived DBPs

Studies also show that shilajit enhances spermatogenesis. Based on animal and human studies, the safety of shilajit is well documented. However, this assessment applies specifically to purified, standardized preparations tested in controlled trials.

Regarding pregnancy: Traditional Ayurvedic texts classify shilajit as contraindicated in pregnancy. The presence of heavy metals — even at levels considered safe for healthy adults — takes on additional significance during fetal development, where lead in particular crosses the placental barrier.

No experimental studies directly evaluating combined use of shilajit with other supplements were identified, though theoretical complementarity and potential antagonism have been discussed. Key challenges include shilajit standardization, contamination risks, and regulatory limitations.

The overall evidence base for safety is characterized as follows: While research summarizes the traditional importance of shilajit for the treatment and prevention of several acute and chronic diseases and health ailments, despite numerous health claims, there are still major gaps in our understanding of its mechanism of action, variability in efficacy, and toxicity profile.

References

Health Conditions

Health conditions that Dibenzo-alpha pyrones may help support.

No conditions available.

Body Systems

Body systems that Dibenzo-alpha pyrones may help support.

No body systems available.